SAN DIEGO, March 12, 2012 /PRNewswire/ -- Gen-Probe
(NASDAQ: GPRO) today announced three changes to its leadership team
in support of its future growth. Brian B. Hansen has been promoted to senior vice
president, global sales and service. Michael J. Watts has been appointed vice
president of LIFECODES and Prodesse; and Albert S. Kildani has joined the Company as
senior director, investor relations and corporate
communications.
(Logo:
http://photos.prnewswire.com/prnh/20120312/LA68580LOGO)
"These changes further strengthen Gen-Probe's ability to drive
profitable, global growth, and reflect our ability to retain and
attract talented individuals to our team," said Carl Hull, Gen-Probe's chairman and chief
executive officer. "Brian's efforts have been critical to our
commercial success over the last six years and this promotion
reflects his many accomplishments in helping us build a world-class
sales and customer support organization. Mike has done an
exceptional job leading our investor relations program while
communicating the Company's strategies and results to the markets
credibly and consistently. A number of us have worked with Al
over the years in various capacities and he has known the Company
and its industry for many years, which will make for a smooth
transition as he replaces Mike."
Hansen has been with Gen-Probe for over six years and has led
the Company's highly respected sales and service organization in
the United States in a number of
increasingly responsible roles during that time. In his new
position, he will oversee the continued geographic expansion of
Gen-Probe's commercial organization throughout the world.
Watts has managed Gen-Probe's investor relations and corporate
communications efforts for over eight years. In his new role,
he will lead the Company's efforts to profitably grow its recently
acquired business units focusing on transplant diagnostics and
infectious disease testing.
Kildani joins Gen-Probe after a 14-year career on Wall Street as
a sell-side research analyst, investment banker, and buy-side
analyst in the healthcare space with a focus on the molecular
diagnostics industry. Al has strong existing relationships
with many of the Company's institutional shareholders and research
analysts.
About Gen-Probe
Gen-Probe is a global leader in the development, manufacture and
marketing of rapid, accurate and cost-effective molecular
diagnostic products and services that are used primarily to
diagnose human diseases, screen donated human blood, and ensure
transplant compatibility. Gen-Probe is headquartered in
San Diego and employs
approximately 1,400 people. For more information, go to
http://www.gen-probe.com.
Caution Regarding Forward-Looking Statements
Any statements in this press release about Gen-Probe's
expectations, beliefs, plans, objectives, assumptions or future
events or performance are not historical facts and are
forward-looking statements. These statements are often, but
not always, made through the use of words or phrases such as
believe, will, expect, anticipate, estimate, intend, plan and
would. For example, statements concerning future financial
performance, the development and commercialization of new products,
regulatory approvals or clearances, customer adoption, and results
of future clinical studies are all forward-looking
statements. Forward-looking statements are not guarantees of
performance. They involve known and unknown risks,
uncertainties and assumptions that may cause actual results, levels
of activity, performance or achievements to differ materially from
those expressed or implied. Some of the risks, uncertainties
and assumptions that could cause actual results to differ
materially from estimates or projections contained in the
forward-looking statements include but are not limited to: (i) the
possibility that we may not meet our financial goals; (ii) the risk
that our commercial expansion efforts will not be successful or
profitable; (iii) the risk that we may not integrate our recent
acquisitions effectively; and (iv) the risk that we will not be
able to retain key executives or attract new ones. The
foregoing describes some, but not all, of the factors that could
affect our ability to achieve results described in any
forward-looking statements. For additional information about
risks and uncertainties we face and a discussion of our financial
statements and footnotes, see documents we file with the SEC,
including our most recent annual report on Form 10-K and all
subsequent periodic reports. We assume no obligation and
expressly disclaim any duty to update any forward-looking statement
to reflect events or circumstances after the date of this news
release or to reflect the occurrence of subsequent events.
Contact:
Al
Kildani
Sr.
director, investor relations and corporate
communications
858-410-8653
|
|
SOURCE Gen-Probe